AQUEOUS EXTRACTION PROCESS OF PLANTS, METHOD THEREOF, AND PRODUCT BY PROCESS
The preparation of an aqueous extract resulting from an aqueous extraction process of Cinnamomum aromaticum, Arctium lappa, Viticis fructus, Lonicera japonica, Acanthopanax gracilistylis, Raphanus sativus, Astragalus membranaceus and Hordeum vulgare and the chemical composition comprising said extract or fraction thereof, and the use of said composition or fraction thereof for treating or preventing cancers and inflammation related diseases, hair loss, stimulating hair growth, increasing energy production, and boosting immunity.
This application is a Continuation of and claims priority in U.S. Non-Provisional patent application Ser. No. 16/590,807 Filed Oct. 2, 2019, which is a Non-Provisional of U.S. Provisional Patent Application 62/740,047 Filed Oct. 2, 2018 and is related to U.S. Non-Provisional patent application Ser. No. 16/686,535, filed Nov. 18, 2019, all of which is incorporated herein by reference.
BACKGROUND OF THE INVENTION 1. Field of the InventionThe present invention relates generally to an aqueous extraction process and method for use thereof, and more specifically to an aqueous extraction process of specific plants for the chemical composition thereof.
2. Description of the Related ArtExisting methods for extracting key compounds or components for generating a chemical composition comprised of an extract thereof do exist. However, these processes have failed to adequately and reliably produce a chemical composition having the results of the present invention.
Heretofore there has not been available a system or method for an aqueous extraction process and resulting extract with the advantages and features of the present invention.
BRIEF SUMMARY OF THE INVENTIONThe present invention generally provides for the preparation of an aqueous extract resulting from an aqueous extraction of individual or mixtures of Cinnamomum cassia, Arctium lappa, Vitex agnus castus, Lonicera japonica, Acanthopanax gracilistylis, Raphanus sativus, Astragalus membranaceus and Hordeum vulgare and the chemical composition comprising said extracts or fractions thereof, and the use of said compositions or fractions thereof for treating or preventing cancers and inflammation related diseases, hair loss, stimulating hair growth, increasing energy production, and boosting immunity.
The resulting extracts include a mixture of naturally occurring biologically active phytochemical compounds that possess a variety of beneficial animal and human health effects.
The drawings constitute a part of this specification and include exemplary embodiments of the present invention illustrating various objects and features thereof.
As required, detailed aspects of the present invention are disclosed herein, however, it is to be understood that the disclosed aspects are merely exemplary of the invention, which may be embodied in various forms. Therefore, specific structural and functional details disclosed herein are not to be interpreted as limiting, but merely as a basis for the claims and as a representative basis for teaching one skilled in the art how to variously employ the present invention in virtually any appropriately detailed manifestation.
Certain terminology will be used in the following description for convenience in reference only and will not be limiting. For example, up, down, front, back, right and left refer to the invention as orientated in the view being referred to which the referral is directed. The words, “inwardly” and “outwardly” refer to directions toward and away from, respectively, the geometric center of the aspect being described and designated parts thereof. Forwardly and rearwardly are generally in reference to the direction of travel, if appropriate. Said terminology will include the words specifically mentioned, derivatives thereof and words of similar meaning.
II. PREFERRED EMBODIMENT STATIC (BATCH) SYSTEM AND AQUEOUS EXTRACTION PROCESSIndividual or a desired mixture of Cinnamomum cassia, Arctium lappa, Vitex agnus castus, Lonicera japonica, Acanthopanax gracilistylis, Raphanus sativus, Astragalus membranaceus and Hordeum vulgare are combined in equal or various amounts by dry weight and placed in a spunbond nonwoven fabric container 14. The fabric container may be placed upon a pedestal 16 within the extraction apparatus 8 for optimal results. The spunbond nonwoven fabric container 14 is sealed and then fixed within the extraction apparatus 8 containing reverse-osmosis membrane filtered purified or distilled water 10 as shown in
For example, by dry weight, for each liter of water, 220 mg of Cinnamomum cassia, 110 mg Arctium lappa, 220 mg Vitex agnus castus, 110 mg Lonicera japonica, 110 mg Acanthopanax gracilistylis, 110 mg Raphanus sativus, 110 mg Astragalus membranaceus and 220 mg Hordeum vulgare are combined and placed in a spunbond nonwoven fabric, and the spunbond nonwoven fabric sealed and then fixed within the extraction apparatus filled with reverse-osmosis membrane filter purified or distilled water. The extraction vessel is closed and then heated to boiling for 3 hrs. Some of vapor is discharged through the water-cooled condenser outlet affixed to the top of the extraction vessel allowing a portion of volatiles to escape while retaining some that are condensed and returned to the extraction vessel. The resulting hot extraction mixture, of these ingredients is referred to as, EPE001, from this point onward, is then filtered in succession via simple vacuum assisted filtration using membrane filters with a pore size not bigger than 10-6 m (1 micron) at 90-100° C., 70-85° C., 40-60° C., 15-30° C., and 5-15° C. providing the final product extract that contains ˜370 mg of biologically active solid ingredients per liter of aqueous extract.
III. ALTERNATIVE EMBODIMENT DYNAMIC (SEMI-CONTINUOUS FLOW) SYSTEM AND AQUEOUS EXTRACTION PROCESS 52This process is made dynamic through the use of a large vessel of purified water 18 which is pumped using a pump 20 into the extraction vessel 8. It is then pulled out of the extraction vessel 8 using a series of valves 22, filters 24, and pumps 20 as shown in
The use of the extract resulting from the aqueous extraction processes as described herein are varied. A first use of the extract would be as a potential cancer therapeutic. This would provide an application to a broad range of solid cancers (neoplasias) due to effects of the extract chemical composition on mitochondrial function in cancer cells (e.g. apoptosis, autophagy, and mitochondrial membrane potential changes) as well as changes in transcriptional activation (promote or inhibit) of key genes associated with cancer progression or suppression. The benefits include a reduction or elimination of side effects common in existing cancer therapeutics. The preparation of the extract as presented herein provides for the delivery of biologically active compounds topically or as an aqueous oral dose. It has a bioactivation and bioavailability increase upon digestion associated with changes in pH. It causes a decrease in the proliferation of cancer cells and an inhibition of genes related to cancer cell growth.
A second use of the extract as presented herein would be an anti-inflammatory therapeutic. It provides a reduction in reactive oxygen species formation in normal cells. It reduces production of inflammatory cytokines. It also provides increased mobility with concurrent decrease in joint pain.
A third use is as an energy supplement. The extract provides an increase in beta-oxidation utilizing fatty acids as a substrate for generation of ATP. It provides increased energy production (e.g. mitochondrial efficiency). It also provides a decrease in glucose dependency as a metabolic substrate, while also reducing inflammation as described above.
A fourth use is as a weight loss supplement. The extract has been shown to increase beta-oxidation utilizing fatty acids as a substrate for generation of ATP. and a decrease in glucose dependency as a metabolic substrate. The extract has also been shown to decrease glucose dependency as a metabolic substrate. These metabolic changes are expected to cause weight loss. The extract has also been shown to provide an inhibition of some known obesity related gene expression.
A fifth use is for its antiviral effectiveness due to increased potential cell membrane resistance and decreased replication capabilities against clinically relevant viral strains including HIV, Influenza Virus, West Nile Virus, Adenovirus, and Polymavirus.
A sixth use is for its antimicrobial effectiveness due to its effectiveness against pathogenic bacterial infections including, Streptococcus sp., Staphylococcus sp., and Listeria sp.
A seventh use is for dermatological stem cell activity, such as for use for hair growth or other uses against skin conditions such as atopic dermatitis, psoriasis, and eczema.
An eighth use is for boosting the immune system. Specifically, inducing pluripotent stem cells to replace depleted populations of T-cell lymphocytes. This population replenishment has direct positive benefits in the mechanism of action and is described in [0027] and [0028].
IV. EXAMPLES AND RESULTS UTILIZING A PRODUCT BY PROCESS OF STATIC (BATCH) SYSTEM AND AQUEOUS EXTRACTION PROCESS 2 OR DYNAMIC (SEMI-CONTINUOUS FLOW) SYSTEM AND AQUEOUS EXTRACTION PROCESS 52In these examples, each of the eight herbs (Cinnamomum cassia, Arctium lappa, Vitex agnus castus, Lonicera japonica, Acanthopanax gracilistylis, Raphanus sativus, Astragalus membranaceus and Hordeum vulgare) were milled to a powder then passed through a 0.21 mm mesh sieve to exclude any large particulates. The powders were combined and placed into a spunbond nonwoven fabric bag and sealed then placed into a vessel containing reverse-osmosis purified water utilizing the static system 2 shown in
Similarly,
Cells treated with the 0.2 μm filtered EPE001 did not show morphological differences, as shown in
Cells treated with EPE001 filtered with the 0.2 μm filter at 80° C. did not show morphological differences in comparison to the untreated control group as shown in
RNA-Seq analysis or Whole Transcriptome Shotgun Sequencing (WTSS) uses a Next-Generation Sequencing (NGS) method to catalog and count the number of RNA transcripts produced in a selected cell culture. This technique can be used as a comparative tool to determine which genes are activated or suppressed and to what degree in different environments—in this example, with and without the presence of the Extract Product. Data collected from RNA-Seq analysis is analyzed utilizing a web-based software application, Ingenuity Pathway Analysis (IPA), produced by QIAGEN Bioinformatics.
For this example, untreated MCF7 breast cancer cells were used as a control. The differences between this control and the MCF7 breast cancer cells treated with EPE001 (filtered at 80° C. with a 0.2 μm filter) using RNA-Seq analysis.
The gene, HGF (hepatocyte growth factor), is involved in cell growth and has higher expression in cancer cells. This gene is downregulated in the presence of EPE001.
The gene, VEGF (vascular endothelial growth factor), has been implicated in promoting blood supply to cancer cells and the metastatic cascade. This gene is downregulated in the presence of EPE001.
The gene, HSPG2 (heparan sulfate proteoglycan 2), is involved in angiogenesis, β-amyloid binding, abnormal morphology and cell proliferation. This gene is also downregulated in the presence of EPE001.
The gene, TP53 (tumor protein 53), is a well-studied tumor suppressor gene that is involved in regulation of cell death and prevention of proliferation. This gene is upregulated in the presence of EPE001.
The gene, NUPR1 (nuclear protein 1), regulates cell death and signals TP53, which is a tumor suppressor gene. This gene is upregulated in the presence of EPE001.
In summary, important upstream regulator genes associated with cancer proliferation are downregulated in the presence of the Extract Product. Important upstream master tumor suppressor genes are upregulated in the presence of EPE001. The RNA-Seq analysis coincides with the physical results seen in
Additionally, treatment of cancer cells with EPE001 resulted in over 2000 molecules that were upregulated or downregulated, many of which are involved in tumor suppression and inhibition of cell growth. Outside of cancer related networks, EPE001 also had an effect on genes associated with DNA replication, recombination and repair, embryonic development, nervous system development and function. These results would suggest an increase in stimulation of healing, stem cell activity, as well as stimulation of hair growth.
There was also an upregulation in genes associated with lipid metabolism which would suggest EPE001 would increase lipid metabolism. This has negative effects on cancer cells because they rely on carbohydrate metabolism for proliferation. This phenomenon also suggests that energy output would increase in healthy cells when using lipid substrates rather than carbohydrates because the process of β-oxidation yields ˜4× as much energy as aerobic respiration (glucose-dependent).
It is to be understood that while certain embodiments and/or aspects of the invention have been shown and described, the invention is not limited therein and encompasses various other embodiments and aspects.
Claims
1. A method of producing an aqueous extract for treatments, the method comprising the steps:
- a) placing a dry mixture within a fibrous container, said dry mixture consisting of: Cinnamomum cassia, Arctium lappa, Vitex agnus castus, Lonicera japonica, Acanthopanax gracilistylis, Raphanus sativus, Astragalus membranaceus and Hordeum vulgare;
- b) placing said fibrous container within an extraction vessel;
- c) filling said extraction vessel with a volume of water;
- c) heating said volume of water with a heating element about said extraction vessel such that draw volatiles, water vapor, and an extraction mixture are generated from said dry mixture within said volume of water;
- e) removing said water vapor with a condensing unit connected to said extraction vessel; and
- f) filtering said extraction mixture out of said extraction vessel.
2. The method of claim 1, further comprising the step:
- mixing 220 mg of Cinnamomum cassia, 110 mg Arctium lappa, 220 mg Vitex agnus castus, 110 mg Lonicera japonica, 110 mg Acanthopanax gracilistylis, 110 mg Raphanus sativus, 110 mg Astragalus membranaceus and 220 mg Hordeum vulgare for each liter of said volume of water to create said dry mixture.
3. The method of claim 2, further comprising the step of treating human breast cancer cells with said extraction mixture.
4. The method of claim 2, further comprising the step of treating human epithelial cells with said extraction mixture.
5. The method of claim 2, further comprising the step of treating human fibroblast cells with said extraction mixture.
6. The method of claim 2, further comprising the step treating a condition selected from a list consisting of cancer; inflammation; fatigue; obesity; viral infections; microbial infections; hair loss; stimulation of dermatological stem cell activity for skin conditions; and boosting the immune system, comprising administering an effective amount of the composition produced through the method of claim 1.
7. The method of claim 6, wherein said treatment is presented in a form selected from a list consisting of: topical; ingestible; and intravenously.
8. A method of treating a condition selected from a list consisting of: wounds, scarring, burns, itching, rashes or irritations, and cosmetic purposes, comprising administering an effective amount of the composition of claim 1.
Type: Application
Filed: Mar 1, 2023
Publication Date: Jun 29, 2023
Inventors: William P. Duncan (Olathe, KS), Lauren S. Gollahon (Lubbock, TX), William C. Putnam (Frisco, TX)
Application Number: 18/115,927